SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

MHRA Expands Casgevy Eligibility to Children Aged 5 and Older

Children aged 5 and older with severe sickle-cell disease or transfusion-dependent β-thalassemia can now be treated with Casgevy, according to the MHRA.

Related stories